Modified Electroconvulsive Therapy Normalizes Plasma GNA13 Following Schizophrenic Relapse.

Objective: GNA13 is an important member of the G protein family, and its coding gene GNA13 has been identified as one of the risk genes for schizophrenia (SCZ). This study aimed to investigate the relationship between GNA13 levels and the clinical symptoms of SCZ following treatment with modified electroconvulsive therapy (MECT).

Methods: This study recruited 82 SCZ patients and 86 healthy controls (HCs). Each SCZ patient received 6 sessions of MECT. The Positive and Negative Syndrome Scale (PANSS) was used to assess SCZ symptom severity. Plasma levels of GNA13 were measured by enzyme-linked immunosorbent assay.

Results: Pretreatment, SCZ patients had a higher GNA13 level than HC ( t = 8.199, P < 0.001). MECT reduced the GNA13 level significantly ( t = 11.13, P < 0.001) and normalized the difference between SCZ and HC ( t = 0.219, P = 0.827). After treatment, the downregulation of GNA13 (ΔGNA13) was negatively correlated with the positive symptoms score reduction rate (ΔP) ( r = -0.379, P = 0.027) and positively correlated with the negative score reduction rate (ΔN) ( r = 0.480, P = 0.004) in females. In both males and females, the receiver operating characteristic curve revealed that the pretreatment GNA13 level could help differentiate SCZ from HC (male: area under the curve = 0.792, P < 0.001; female: area under the curve = 0.814, P < 0.001).

Conclusion: The reduced expression of GNA13 after MECT may be related to the exhibition of both negative and positive symptoms of SCZ in female patients.